Intranasal Oxytocin for ObesityFranziska Plessow, Elizabeth A. Lawson, Arvin Kheterpal et al.|NEJM Evidence|2024Cited by 20
Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With ObesityAnna Aulinas, Elizabeth A. Lawson, Francesca Galbiati et al.|The Journal of Clinical Endocrinology & Metabolism|2025Cited by 2
FRI004 Sex Differences In Oxytocin And Arginine-Vasopressin Levels Around A Standardized Meal In Adults With ObesityMarie‐Louis Wronski, Elizabeth A. Lawson, James T Sanislow et al.|Journal of the Endocrine Society|2023Cited by 0
7458 Eight Weeks Intranasal Oxytocin vs. Placebo Does Not Impact Circulating Oxytocin or Arginine-Vasopressin Levels in Adults With ObesityAnna Aulinas, Elizabeth A. Lawson, C. Sue Carter et al.|Journal of the Endocrine Society|2024Cited by 0
OR35-06 Four-week intranasal oxytocin treatment modulates functional brain activation in reward, homeostatic, and cognitive control regions in adults with obesityMarie‐Louis Wronski, Elizabeth A. Lawson, Arjun Shreekumar et al.|Journal of the Endocrine Society|2025Cited by 0